Shop

Ferintus 100 mgFerintus 100 mg is indicated for the treatment of?iron deficiency anemia?in adult patients- Who have intolerance to oral iron or have had unsatisfactory response to oral iron Who have non-dialysis?dependent chronic kidney disease. Theropeutic ClassParenteral Iron PreparationsPharmacologyNon-dextran, IV is a colloidal iron hydroxide in complex with carboxymaltose, a carbohydrate polymer that releases iron; replaces iron stores found in hemoglobin, myoglobin, and enzymes; works to transport oxygen via hemoglobin Macrophage engulf FCM from blood and control iron release. Transferrin saturates and, Iron into the liver, spleen and Bone marrow.Dosage & Administration of Ferintus 100 mgFor patients weighing 50 kg or more: Give Ferintus 100 mg in two doses separated by at least 7 days. Give each dose as 750 mg for a total cumulative dose not to exceed 1500 mg of iron per course.For patients weighing less than 50 kg: Give Ferintus 100 mg in two doses separated by at least 7 days. Give each dose as 15 mg/kg body weight for a total cumulative dose not to exceed 1500 mg of iron per course.The dosage of Ferintus 100 mg is expressed in mg of elemental iron. Each mL of Ferintus 100 mg contains 50 mg of elemental iron. Ferintus 100 mg treatment may be repeated if iron deficiency?anemia?reoccurs.Administer Ferintus 100 mg intravenously, either as an undiluted slow intravenous push or by infusion. When administering as a slow intravenous push, give at the rate of approximately 100 mg (2 mL) per minute. When administered via infusion, dilute up to 750 mg of iron in no more than 250 mL of sterile 0.9% sodium chloride injection, USP, such that the concentration of the infusion is not less than 2 mg of iron per mL and administer over at least 15 minutes.When added to an infusion bag containing 0.9% Sodium Chloride Injection, USP, at concentrations ranging from 2 mg to 4 mg of iron per mL, Ferintus 100 mg solution is physically and chemically stable for 72 hours when stored at room temperature. To maintain stability, do not dilute to concentrations less than 2 mg iron/mL.Inspect?parenteral?drug products visually for the absence of particulate matter and discoloration prior to administration. The product contains no preservatives. Each vial of Ferintus 100 mg is intended for single use only. Any unused drug remaining after injection must be discarded.Avoid extravasation of Ferintus 100 mg since brown discoloration of the extravasation site may be long lasting. Monitor for extravasation. If extravasation occurs, discontinue the Ferintus 100 mg administration at that site.Dosage of Ferintus 100 mgFor patients weighing 50 kg or more: Give Ferintus 100 mg in two doses separated by at least 7 days. Give each dose as 750 mg for a total cumulative dose not to exceed 1500 mg of iron per course.For patients weighing less than 50 kg: Give Ferintus 100 mg in two doses separated by at least 7 days. Give each dose as 15 mg/kg body weight for a total cumulative dose not to exceed 1500 mg of iron per course.The dosage of Ferintus 100 mg is expressed in mg of elemental iron. Each mL of Ferintus 100 mg contains 50 mg of elemental iron. Ferintus 100 mg treatment may be repeated if iron deficiency?anemia?reoccurs.Administer Ferintus 100 mg intravenously, either as an undiluted slow intravenous push or by infusion. When administering as a slow intravenous push, give at the rate of approximately 100 mg (2 mL) per minute. When administered via infusion, dilute up to 750 mg of iron in no more than 250 mL of sterile 0.9% sodium chloride injection, USP, such that the concentration of the infusion is not less than 2 mg of iron per mL and administer over at least 15 minutes.When added to an infusion bag containing 0.9% Sodium Chloride Injection, USP, at concentrations ranging from 2 mg to 4 mg of iron per mL, Ferintus 100 mg solution is physically and chemically stable for 72 hours when stored at room temperature. To maintain stability, do not dilute to concentrations less than 2 mg iron/mL.Inspect?parenteral?drug products visually for the absence of particulate matter and discoloration prior to administration. The product contains no preservatives. Each vial of Ferintus 100 mg is intended for single use only. Any unused drug remaining after injection must be discarded.Avoid extravasation of Ferintus 100 mg since brown discoloration of the extravasation site may be long lasting. Monitor for extravasation. If extravasation occurs, discontinue the Ferintus 100 mg administration at that site.Interaction of Ferintus 100 mgThere are no known drug interactions and none well documented.ContraindicationsHypersensitivity to any of its components.Side Effects of Ferintus 100 mgNausea, Hypertension, Flushing, Decreased blood phosphorus, Dizziness, Vomiting, Pruritus, Rash, Urticaria, Wheezing, Injection site discoloration, Headache, Increased alanine aminotransferase), Dysgeusia, Hypotension, Constipation, Serious anaphylactic/anaphylactoid reactionsPregnancy & LactationPregnancy Category C. Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risksPrecautions & WarningsHypersensitivity Reactions:?Serious hypersensitivity reactions, including anaphylactic-type reactions, some of which have been life-threatening and fatal, have been reported in patients receiving Ferric carboxymaltose. Patients may present with shock, clinically significant hypotension, loss of consciousness, and/or collapse. Monitor patients for signs and symptoms of hypersensitivity during and after Ferric carboxymaltose administration for at least 30 minutes and until clinically stable following completion of the infusion. Only administer Ferric carboxymaltose when personnel and therapies are immediately available for the treatment of serious hypersensitivity reactions. Other serious or severe adverse reactions potentially associated with hypersensitivity which included, but not limited to, pruritus, rash, urticaria, wheezing, or hypotension may occur.Hypertension:?Transient elevations in systolic blood pressure, sometimes occurring with facial flushing, dizziness, or nausea were observed. These elevations generally occurred immediately after dosing and resolved within 30 minutes. Monitor patients for signs and symptoms of hypertension following each Ferric carboxymaltose administration.Storage ConditionsDo not store above 30?C. Do not freeze.Drug ClassesParenteral Iron PreparationsMode Of ActionNon-dextran, IV is a colloidal iron hydroxide in complex with carboxymaltose, a carbohydrate polymer that releases iron; replaces iron stores found in hemoglobin, myoglobin, and enzymes; works to transport oxygen via hemoglobin Macrophage engulf FCM from blood and control iron release. Transferrin saturates and, Iron into the liver, spleen and Bone marrow.PregnancyPregnancy Category C. Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks

Ferintus 500 mgFerintus 500 mg is indicated for the treatment of?iron deficiency anemia?in adult patients- Who have intolerance to oral iron or have had unsatisfactory response to oral iron Who have non-dialysis?dependent chronic kidney disease. Theropeutic ClassParenteral Iron PreparationsPharmacologyNon-dextran, IV is a colloidal iron hydroxide in complex with carboxymaltose, a carbohydrate polymer that releases iron; replaces iron stores found in hemoglobin, myoglobin, and enzymes; works to transport oxygen via hemoglobin Macrophage engulf FCM from blood and control iron release. Transferrin saturates and, Iron into the liver, spleen and Bone marrow.Dosage & Administration of Ferintus 500 mgFor patients weighing 50 kg or more: Give Ferintus 500 mg in two doses separated by at least 7 days. Give each dose as 750 mg for a total cumulative dose not to exceed 1500 mg of iron per course.For patients weighing less than 50 kg: Give Ferintus 500 mg in two doses separated by at least 7 days. Give each dose as 15 mg/kg body weight for a total cumulative dose not to exceed 1500 mg of iron per course.The dosage of Ferintus 500 mg is expressed in mg of elemental iron. Each mL of Ferintus 500 mg contains 50 mg of elemental iron. Ferintus 500 mg treatment may be repeated if iron deficiency?anemia?reoccurs.Administer Ferintus 500 mg intravenously, either as an undiluted slow intravenous push or by infusion. When administering as a slow intravenous push, give at the rate of approximately 100 mg (2 mL) per minute. When administered via infusion, dilute up to 750 mg of iron in no more than 250 mL of sterile 0.9% sodium chloride injection, USP, such that the concentration of the infusion is not less than 2 mg of iron per mL and administer over at least 15 minutes.When added to an infusion bag containing 0.9% Sodium Chloride Injection, USP, at concentrations ranging from 2 mg to 4 mg of iron per mL, Ferintus 500 mg solution is physically and chemically stable for 72 hours when stored at room temperature. To maintain stability, do not dilute to concentrations less than 2 mg iron/mL.Inspect?parenteral?drug products visually for the absence of particulate matter and discoloration prior to administration. The product contains no preservatives. Each vial of Ferintus 500 mg is intended for single use only. Any unused drug remaining after injection must be discarded.Avoid extravasation of Ferintus 500 mg since brown discoloration of the extravasation site may be long lasting. Monitor for extravasation. If extravasation occurs, discontinue the Ferintus 500 mg administration at that site.Dosage of Ferintus 500 mgFor patients weighing 50 kg or more: Give Ferintus 500 mg in two doses separated by at least 7 days. Give each dose as 750 mg for a total cumulative dose not to exceed 1500 mg of iron per course.For patients weighing less than 50 kg: Give Ferintus 500 mg in two doses separated by at least 7 days. Give each dose as 15 mg/kg body weight for a total cumulative dose not to exceed 1500 mg of iron per course.The dosage of Ferintus 500 mg is expressed in mg of elemental iron. Each mL of Ferintus 500 mg contains 50 mg of elemental iron. Ferintus 500 mg treatment may be repeated if iron deficiency?anemia?reoccurs.Administer Ferintus 500 mg intravenously, either as an undiluted slow intravenous push or by infusion. When administering as a slow intravenous push, give at the rate of approximately 100 mg (2 mL) per minute. When administered via infusion, dilute up to 750 mg of iron in no more than 250 mL of sterile 0.9% sodium chloride injection, USP, such that the concentration of the infusion is not less than 2 mg of iron per mL and administer over at least 15 minutes.When added to an infusion bag containing 0.9% Sodium Chloride Injection, USP, at concentrations ranging from 2 mg to 4 mg of iron per mL, Ferintus 500 mg solution is physically and chemically stable for 72 hours when stored at room temperature. To maintain stability, do not dilute to concentrations less than 2 mg iron/mL.Inspect?parenteral?drug products visually for the absence of particulate matter and discoloration prior to administration. The product contains no preservatives. Each vial of Ferintus 500 mg is intended for single use only. Any unused drug remaining after injection must be discarded.Avoid extravasation of Ferintus 500 mg since brown discoloration of the extravasation site may be long lasting. Monitor for extravasation. If extravasation occurs, discontinue the Ferintus 500 mg administration at that site.Interaction of Ferintus 500 mgThere are no known drug interactions and none well documented.ContraindicationsHypersensitivity to any of its components.Side Effects of Ferintus 500 mgNausea, Hypertension, Flushing, Decreased blood phosphorus, Dizziness, Vomiting, Pruritus, Rash, Urticaria, Wheezing, Injection site discoloration, Headache, Increased alanine aminotransferase), Dysgeusia, Hypotension, Constipation, Serious anaphylactic/anaphylactoid reactionsPregnancy & LactationPregnancy Category C. Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risksPrecautions & WarningsHypersensitivity Reactions:?Serious hypersensitivity reactions, including anaphylactic-type reactions, some of which have been life-threatening and fatal, have been reported in patients receiving Ferric carboxymaltose. Patients may present with shock, clinically significant hypotension, loss of consciousness, and/or collapse. Monitor patients for signs and symptoms of hypersensitivity during and after Ferric carboxymaltose administration for at least 30 minutes and until clinically stable following completion of the infusion. Only administer Ferric carboxymaltose when personnel and therapies are immediately available for the treatment of serious hypersensitivity reactions. Other serious or severe adverse reactions potentially associated with hypersensitivity which included, but not limited to, pruritus, rash, urticaria, wheezing, or hypotension may occur.Hypertension:?Transient elevations in systolic blood pressure, sometimes occurring with facial flushing, dizziness, or nausea were observed. These elevations generally occurred immediately after dosing and resolved within 30 minutes. Monitor patients for signs and symptoms of hypertension following each Ferric carboxymaltose administration.Storage ConditionsDo not store above 30?C. Do not freeze.Drug ClassesParenteral Iron PreparationsMode Of ActionNon-dextran, IV is a colloidal iron hydroxide in complex with carboxymaltose, a carbohydrate polymer that releases iron; replaces iron stores found in hemoglobin, myoglobin, and enzymes; works to transport oxygen via hemoglobin Macrophage engulf FCM from blood and control iron release. Transferrin saturates and, Iron into the liver, spleen and Bone marrow.PregnancyPregnancy Category C. Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks